Java will use this investment to develop our proteomic services, in particular to further refine our methods for acquisition and analysis of samples for proteomic analysis in clinical trials, and to validate this approach in clinical populations. Following a successful pilot application in cardiovascular disease, we will conduct some additional method development in collaboration with the UCD Conway Institute, and apply this in a larger clinical setting in 2015. The Enterprise Ireland grant will support the development of this approach into a more mature service for our clients.
This innovative clinical proteomics service gives clients in the pharmaceutical industry more detailed information in early phase clinical trials. Proteomics allows the identification of biomarkers of drug effects, or the mapping of pathways altered by new drugs. Clients can use this data to show clinical proof of concept in early phase clinical trials, or obtain more information on their drug’s actions before embarking on more expensive phase II or phase III clinical trials.